Anavex Life Sciences Corp (AVXL)

[falconer66a]

Yes, merely 'nonsense.' Gotta be SO careful.

Yes, be very careful about ‘nonsense’ in regard to Anavex 2-73. Here’s the ‘nonsense’ the author was 'pumping' in the article. I’ve bold-faced particularly nonsensical statements:

NAVEX2-73: The leading sigma-1 agonist under development is ANAVEX2-73, an amino-tetrahydrofuran derivative and mixed muscarinic/sigma-1 receptor agonist.16 At present, 3 active clinical trials involve ANAVEX2-73: one for Parkinson disease with dementia and 2 for Alzheimer disease.17 Another clinical trial for Rett syndrome is planned, announced in October 2018 by manufacturer Anavex Life Sciences.

The most advanced data for ANAVEX2-73 come from a completed phase 2a trial involving patients with Alzheimer disease.18,19 The study involved 32 patients with mild to moderate disease, with baseline Mini-Mental State Examination (MMSE) scores between 16 and 28. The initial 5 weeks of the study involved crossover from oral to intravenous administration, followed by a year of oral therapy. Primary endpoints focused on safety, dose, and tolerability, while secondary endpoints evaluated efficacy measured by MMSE, Alzheimer’s Disease Cooperative Study-Activities of Daily Living inventory, and electroencephalography (EEG)/event-related potentials (ERPs). After 1 year, multivariable analysis showed a strong relationship between high doses (30 mg and 50 mg) and improved responses compared with patients who received low doses (3 mg and 5 mg) and had poor responses. The agent was very well tolerated, with no serious or clinically significant adverse effects.

The extended period of this trial has been ongoing for 3 years. The most recent findings echoed earlier reports, namely that the high-dose group continued to show significantly better responses in functional and cognitive endpoints than patients treated with low doses. The investigators also highlighted 2 genomic biomarkers that continued to be significantly associated with responses: SIGMAR1 and COMT. The former suggests that sigma-1 activation is a critical component of patient responses. In a press release issued by Anavex, Harald Hampel, MD, PhD, professor at the Sorbonne in Paris reflected on the biomarker findings: “These results further confirm the impact of actionable genetic variants that were previously identified through a full, unbiased genomic analysis of ANAVEX2-73 in Alzheimer’s disease, raising optimism for the future of biomarker-guided precision medicine to effectively combat this devastating disease.”

The author, Eduardo Benarroch, MD, whoever he was, sure seemed to pump the Anavex drug. He stated that at high doses it got good therapeutic results (imagine that, for Alzheimer's disease of all things).

Then, he claimed, "The agent was very well tolerated, with no serious or clinically significant adverse effects." Wow. He's really pumping.

Of course, all of this was way back in 2019, in a major medical website, NeurologyLive, by a fellow with an "MD" after his name. At least, he's probably better informed than your standard run of the classroom high school biology teacher.

Gotta be careful. In his pumping, he must have left out a lot of bad stuff. Fortunately, with the three blarcamesine clinical trials coming to an end this year, we'll get the real story.

OOPS! Big error. The article was written or provided by one Will Pass, DVM. The guy's a veterinarian, of all things. What could dog doctors know about the safety or efficacy of Anavex 2-73? More 'nonsense.'